Barry Ticho Sells 2,006 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 2,006 shares of the firm’s stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $29.78, for a total value of $59,738.68. Following the transaction, the insider directly owned 17,170 shares of the company’s stock, valued at approximately $511,322.60. This represents a 10.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Barry Ticho also recently made the following trade(s):

• On Wednesday, December 3rd, Barry Ticho sold 2,014 shares of Stoke Therapeutics stock. The shares were sold at an average price of $30.65, for a total value of $61,729.10.
• On Monday, November 3rd, Barry Ticho sold 5,931 shares of Stoke Therapeutics stock. The shares were sold at an average price of $25.72, for a total value of $152,545.32.

Stoke Therapeutics Stock Performance

NASDAQ:STOK opened at $31.05 on Friday. Stoke Therapeutics, Inc. has a 52 week low of $5.35 and a 52 week high of $38.69. The firm’s fifty day moving average is $28.90 and its 200-day moving average is $19.69. The firm has a market cap of $1.77 billion, a P/E ratio of 46.34 and a beta of 1.14.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.11). The firm had revenue of $10.63 million for the quarter, compared to the consensus estimate of $6.06 million. Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%. As a group, sell-side analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on STOK shares. BTIG Research reiterated a “buy” rating and issued a $39.00 target price on shares of Stoke Therapeutics in a report on Wednesday, November 5th. Chardan Capital upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Wednesday, November 19th. Weiss Ratings restated a “hold (c)” rating on shares of Stoke Therapeutics in a report on Monday. JPMorgan Chase & Co. boosted their target price on Stoke Therapeutics from $15.00 to $25.00 and gave the company a “neutral” rating in a research report on Monday, November 3rd. Finally, Needham & Company LLC upped their price target on Stoke Therapeutics from $22.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, October 10th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, Stoke Therapeutics has a consensus rating of “Buy” and a consensus target price of $31.00.

Hedge Funds Weigh In On Stoke Therapeutics

Large investors have recently bought and sold shares of the stock. XTX Topco Ltd purchased a new position in Stoke Therapeutics during the first quarter worth about $267,000. US Bancorp DE raised its holdings in shares of Stoke Therapeutics by 9,743.9% in the 1st quarter. US Bancorp DE now owns 11,222 shares of the company’s stock worth $75,000 after purchasing an additional 11,108 shares during the period. Vanguard Group Inc. lifted its stake in Stoke Therapeutics by 1.9% in the first quarter. Vanguard Group Inc. now owns 2,784,202 shares of the company’s stock valued at $18,515,000 after purchasing an additional 53,004 shares during the last quarter. Invesco Ltd. grew its holdings in Stoke Therapeutics by 117.0% during the first quarter. Invesco Ltd. now owns 26,183 shares of the company’s stock valued at $174,000 after purchasing an additional 14,118 shares during the period. Finally, Nuveen LLC purchased a new stake in Stoke Therapeutics in the first quarter worth $719,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.